ALB and Hypoalbuminemia: In CD patients, the higher the albumin levels, the higher the clinical remission rate after a dose escalation of infliximab [123]; while hypoalbuminemia is associated with a worse outcome, a greater risk of relapse and interrupting anti-TNF therapy for albumin serum levels < 3.5 g/dL (p = 0.0274) [124,125,126].